Curis Inc (CRIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curis Inc (CRIS) has a cash flow conversion efficiency ratio of -0.708x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.00 Million) by net assets ($12.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Curis Inc to measure how much of total assets are equity-financed.
Curis Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Curis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Curis Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Curis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Australian Rare EARTHS Ltd
AU:AR3
|
-0.007x |
|
SenzaGen AB
ST:SENZA
|
-0.052x |
|
Geratherm Medical AG
XETRA:GME
|
0.021x |
|
MDB Capital Holdings, LLC Class A common
NASDAQ:MDBH
|
-0.052x |
|
Sigmaroc PLC
LSE:SRC
|
0.118x |
|
Bimergen Energy Corporation
NYSE:BESS
|
0.086x |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
0.035x |
|
Zamet Industry SA
WAR:ZMT
|
0.073x |
Annual Cash Flow Conversion Efficiency for Curis Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Curis Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Curis Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.46 Million | $-27.20 Million | -4.980x | -175.50% |
| 2024-12-31 | $-6.00 Million | $-39.56 Million | 6.596x | +437.58% |
| 2023-12-31 | $19.67 Million | $-38.43 Million | -1.954x | -67.40% |
| 2022-12-31 | $46.55 Million | $-54.34 Million | -1.167x | -181.44% |
| 2021-12-31 | $90.71 Million | $-37.62 Million | -0.415x | -110.55% |
| 2020-12-31 | $130.67 Million | $-25.74 Million | -0.197x | -125.49% |
| 2019-12-31 | $-33.91 Million | $-26.20 Million | 0.773x | -88.44% |
| 2018-12-31 | $-4.50 Million | $-30.07 Million | 6.687x | +431.80% |
| 2017-12-31 | $23.99 Million | $-48.35 Million | -2.015x | -64.70% |
| 2016-12-31 | $29.27 Million | $-35.81 Million | -1.224x | -164.09% |
| 2015-12-31 | $64.51 Million | $-29.89 Million | -0.463x | +17.92% |
| 2014-12-31 | $29.78 Million | $-16.81 Million | -0.564x | -167.31% |
| 2013-12-31 | $45.17 Million | $-9.54 Million | -0.211x | +52.37% |
| 2012-12-31 | $34.27 Million | $-15.19 Million | -0.443x | -287.44% |
| 2011-12-31 | $39.88 Million | $-4.56 Million | -0.114x | -219.74% |
| 2010-12-31 | $45.52 Million | $-1.63 Million | -0.036x | +84.41% |
| 2009-12-31 | $33.05 Million | $-7.59 Million | -0.230x | +31.30% |
| 2008-12-31 | $37.22 Million | $-12.44 Million | -0.334x | -82.17% |
| 2007-12-31 | $46.84 Million | $-8.59 Million | -0.183x | -10.14% |
| 2006-12-31 | $35.90 Million | $-5.98 Million | -0.167x | +22.23% |
| 2005-12-31 | $38.00 Million | $-8.14 Million | -0.214x | -42.93% |
| 2004-12-31 | $48.91 Million | $-7.33 Million | -0.150x | +40.33% |
| 2003-12-31 | $38.87 Million | $-9.76 Million | -0.251x | +32.68% |
| 2002-12-31 | $18.54 Million | $-6.92 Million | -0.373x | -51.50% |
| 2001-12-31 | $101.02 Million | $-24.88 Million | -0.246x | -76.21% |
| 2000-12-31 | $168.81 Million | $-23.59 Million | -0.140x | +77.84% |
| 1999-12-31 | $23.42 Million | $-14.77 Million | -0.631x | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more